ORTEXORTEX News
Tracking AMCR? Get live short interest, options flow, and signals on ORTEX.Sign up free →
AM
Earnings PreviewAMCR

Amcor Options Flip Bearish Ahead of Q1 Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 4 Nov 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Amcor heads into its November 4 Q1 results with options positioning having shifted sharply since the last preview, the call skew that defined the setup three days ago has reversed into the most defensive read in recent weeks.

The options reversal is the standout change. The put/call ratio has dropped to 0.38, nearly two standard deviations below its 20-day average of 0.48. That is the most call-heavy reading of the past month, but the direction of travel on the day tells a different story: the stock fell 4.2% on November 3 to close at $46.96, erasing much of the week's earlier gain. The PCR z-score of negative 2.0 reflects a surge in call open interest relative to puts, which at this level can indicate either genuine bullish conviction or short-dated speculation ahead of a catalyst. The stock is still up 12% over the past month, so bulls have not been wrong, but the single-session drop into the print sharpens the question of whether the move has been fully priced.

The debate between bulls and bears turns on valuation and earnings trajectory. The mean analyst price target is around $50, implying roughly 7% upside from current levels, with Citigroup and BofA Securities holding Buy ratings and targets of $52 and $51 respectively. UBS initiated at Buy with a $56 target in August. Against that, JP Morgan downgraded to Neutral after the August print, raising its target only modestly to $47, essentially calling the stock fairly valued at current prices. Wells Fargo has maintained Equal-Weight throughout, most recently with a $44 target. EPS momentum ranks in the bottom quarter of the universe on both 30-day and 90-day measures, and forward earnings estimates are still pointing lower year on year. The PE of 11.3x and EV/EBITDA of 9.3x are not demanding, and the dividend score ranks in the 95th percentile, which anchors the income case. But the earnings yield factor score of 74 sits alongside an EPS surprise rank of just 44, meaning the value is visible but the company has not been consistently beating expectations.

Short interest has edged higher since the previous note but remains modest. Shares short rose about 14% over the past month to 1.0% of the free float, extending the accumulation trend flagged on October 31. As noted then, the absolute level is too low to create squeeze dynamics. The borrow market confirms this: availability is 200%, meaning two shares are available to borrow for every one currently shorted, and cost to borrow is 0.48%. Neither figure has moved in a way that changes the picture from three days ago.

Invesco stands out among institutional holders, adding 13.4 million shares in the most recent reported quarter to reach 3.7% of the company, a materially larger move than any other top holder. BlackRock and State Street each hold roughly 7% and added modestly. The print will test whether Amcor's volume and margin recovery is durable enough to justify both the 12% one-month rally and the emerging divergence between call-heavy options positioning and a stock that just gave back 4% in a single session.

Stocks in this article

See the live data behind this article on ORTEX.

Open AMCR on ORTEX →

How this article was generated

Generated
4 Nov 2026, 04:13
Data as of
4 Nov 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.